qumas edms · biovia
QUMAS EDMS: Use Cases & Features for Life Sciences
October 23, 2025
Updated August 12, 2026
15 min read
Learn about Dassault Systèmes' QUMAS EDMS for life sciences. This guide covers its features, EDMS 2026 release, AI integration, and use cases for GxP and 21 CFR Part 11 compliance.
- 01QUMAS EDMS is a cloud-based, Part 11-oriented document and quality management system for life sciences, now part of Dassault Systemes' BIOVIA/3DEXPERIENCE platform, with more than 300 global customer deployments reported by Dassault.
- 02Dassault-reported customer metrics include 20-40% lower SOP management costs, 30% faster document cycles, and 60% higher first-time regulatory submission success, though these are vendor-cited figures rather than independent audits.
- 03The global QMS for life sciences market was valued at USD 2.81 billion in 2024 and is projected to reach USD 6.54 billion by 2033, a 9.7% CAGR, indicating strong sector growth supporting EDMS adoption.
- 04Vertex Pharmaceuticals' Connect 2014 case study shows QUMAS DocCompliance used for about 8 years to replace FTP and email for secure collaboration with external partners and CROs, with no public ROI metrics reported.
- 05FDA does not certify individual electronic systems such as QUMAS EDMS; each regulated organization must independently validate that its configured system meets applicable Part 11 and predicate-rule requirements.
- 06Regulatory change is active into 2026: FDA's QMSR took effect February 2, 2026, FDA issued final Computer Software Assurance guidance in February 2026, and the EU's draft GMP Annex 11/22 consultation closed 7 October 2025.
Executive Summary
QUMAS EDMS (Electronic Document Management System) is a cloud-based compliance solution within Dassault Systèmes’ BIOVIA portfolio, specifically aimed at highly regulated industries. Initially developed by independent firm Qumas (founded 1994), the technology specializes in document and quality management for life sciences and other regulated sectors (e.g. pharmaceuticals, biotechnology, medical devices). QUMAS EDMS is explicitly designed to meet standards such as FDA 21 CFR Part 11 and GxP regulations ([1]) ([2]). Tailored use cases include management of policies, SOPs, clinical and regulatory documents, training, and audit workflows; CAPA and related quality-process workflows can be handled through integration with QUMAS EQMS. Today the system is part of Dassault’s 3DEXPERIENCE/ENOVIA platform (following Accelrys’s 2013 acquisition of QUMAS and Dassault’s 2014 acquisition of Accelrys) ([2]) ([3]). A Dassault QUMAS EDMS datasheet states that the system has more than 300 global customer deployments ([4]), with reported performance improvements (e.g. 20–40% lower SOP management costs, 30% faster document cycles, 60% higher first-time regulatory submission success) ([5]). For example, Vertex Pharmaceuticals (biotechnology) has used QUMAS’s DocCompliance EDMS for document collaboration across partner networks ([6]). This report analyzes the history, functionality, user base, and case studies of QUMAS EDMS, drawing on vendor literature, market data, and industry research.
QUMAS EDMS global customer deployments reported by Dassault
reported faster document cycles from QUMAS EDMS use
reported increase in first-time regulatory submission success
auditable events captured in the QUMAS EDMS audit trail
Introduction and Background
Electronic Document Management Systems (EDMS) have become indispensable in regulated industries, as companies digitalize SOPs, batch records, and regulatory submissions. Dassault Systèmes’ QUMAS EDMS is one such solution, delivering a data-centric, cloud-based platform for quality and compliance. According to Dassault, life sciences companies face critical quality challenges (for example, FDA citations insist on fully written and followed quality procedures) and the need for remote collaboration, especially highlighted during crises like the COVID-19 pandemic ([7]). In this context, QUMAS EDMS aims to ensure that documentation and processes remain compliant and accessible.
Origins: QUMAS began as an independent company in Ireland (1994), focusing on compliance software for life sciences. In December 2013, R&D informatics firm Accelrys acquired QUMAS for ~$50M ([2]), integrating its document- and process-management capabilities. A few months later, in April 2014 Dassault Systèmes acquired Accelrys (renaming it BIOVIA) ([3]). As a result, QUMAS EDMS became part of Dassault’s 3DEXPERIENCE platform under the BIOVIA brand. The modern solution is often referred to as “BIOVIA/ENOVIA QUMAS EDMS” and is supported with regular updates, including the QUMAS EDMS 2026 release, announced November 5, 2025. Dassault’s release notice lists Solr 9.9, PDF-related updates, and numerous fixed defects ([8]). Industry sources observe that QUMAS’s 20-year history in life sciences compliance means “it has refined documentation of compliance with global mandates” and has a strong track record in large-scale regulated deployments ([9]) ([10]).
Scope and Positioning: QUMAS EDMS is explicitly targeted to life sciences and similar regulated industries ([2]). Its marketing states it is a “leader in Quality and Compliance Management Solutions for the Life Sciences sector” with hundreds of global deployments ([11]). Dassault markets QUMAS EDMS as supporting 21 CFR Part 11 controls, including document control, electronic signatures, audit trails, and integrated quality processes ([1]). FDA does not certify individual electronic systems; each regulated organization must determine whether its configured and validated intended use meets applicable Part 11 and predicate-rule requirements ([12]) ([13]). In essence, QUMAS EDMS moves organizations from static file storage to an “intelligent Quality Content Control” paradigm ([1]). The platform supports SOP creation/retirement, ALCOA+ data integrity, audit planning, CAPA workflows, and even electronic common technical document (eCTD) submissions to agencies (FDA, EMA, PMDA) ([14]) ([2]).
- 1994QUMAS founded
Independent company founded in Ireland, focusing on compliance software for life sciences.
- Dec 2013Accelrys acquires QUMAS~$50M
R&D informatics firm Accelrys acquired QUMAS for approximately $50M, integrating its document and process management capabilities.
- Apr 2014Dassault Systemes acquires Accelrys
Dassault Systemes acquired Accelrys and renamed it BIOVIA, bringing QUMAS EDMS into the 3DEXPERIENCE platform.
- Nov 2025QUMAS EDMS 2026 release announced
Dassault announced the QUMAS EDMS 2026 release, with Solr 9.9, PDF-related updates, and numerous fixed defects.
- Feb 2026FDA QMSR takes effect
FDA's Quality Management System Regulation became effective, amending 21 CFR Part 820 to incorporate ISO 13485:2016 by reference.
- Oct 2025EU GMP Annex 11/22 consultation closes
European Commission's consultation on draft revisions to EU GMP Chapter 4 and Annex 11, plus a new Annex 22 on artificial intelligence, closed with no stated final-issuance date.
QUMAS EDMS Features and Benefits
QUMAS EDMS is modular. Key functional components include Enterprise Content Management (ECM), Electronic Document Control, Learning Management (LMS), and Batch Data Management ([15]), covering the full document lifecycle from authoring through approval, distribution, retention, and disposition. A sampling of features (drawn from product literature) illustrates the platform’s capabilities:
- Electronic Document Control: Create, review, approve and digitally sign policies, SOPs, manuals, and reports. You can drag-and-drop Word/PDF content into workflows, track version history, compare changes, and enforce that only the latest approved version is active ([5]). Access is permission-controlled, and compliance (21 CFR Part 11) is built into the processes ([1]) ([16]).
- Training Management: The integrated LMS assigns SOP-reading and certification tasks. Each employee has a personalized training record of assigned tasks (outstanding or completed), and management can view certification status by person or department ([17]). This ensures everyone acknowledges new procedures as part of ongoing compliance.
- Regulatory Submission Support: QUMAS can manage eCTD content generation and submission tracking. It provides templates and collaboration tools across Regulatory Affairs, Clinical, and Quality teams. It automates filings (eCTD, NeeS, CTA, etc.) to agencies like FDA/EMA in compliance with submission standards ([14]).
- Workflow Automation: Complex document workflows are configurable. For example, QUMAS EDMS supports five GxP-specific document types (procedures, methods, etc.) and corresponding automated SOP lifecycles designed to align with best practices ([18]). Administrators define roles/groups and link them to document types/workflows via a visual workflow engine ([19]) ([15]).
- Query & Retrieval: Users can search documents by standard attributes (title, author, date) or custom metadata (e.g. product name, supplier). The search retrieves the latest controlled version, which can be exported or printed as needed ([20]).
- Audit & Reporting: Dassault’s QUMAS EDMS datasheet describes a comprehensive, secure audit trail capturing more than 270 auditable events ([4]). Built-in reports (expiry, authorizations, etc.) help managers monitor compliance and review cycles.
These modules deliver measurable customer benefits. Dassault’s site cites customer-reported metrics, for example:
- 20–40% reduction in SOP management costs, 20–30% faster SOP review time, 30% shorter documentation cycle times, and a 60% increase in first-time success of regulatory submissions ([5]).
Table 1 below summarizes these reported improvements:
Such gains stem from eliminating manual bottlenecks and ensuring only current documents are used. For example, by automating version control and notifications, companies avoid errors from outdated SOPs. Likewise, having a unified platform lets Quality and Regulatory teams collaborate more efficiently across locations.
Drag-and-drop Word/PDF content into workflows and track version history as documents are created.
Documents are created, reviewed, approved and digitally signed as policies, SOPs, manuals, and reports.
The integrated LMS assigns SOP-reading and certification tasks so employees acknowledge new procedures.
Full document lifecycle spans authoring through approval, distribution, retention, and disposition, with search retrieving the latest controlled version.
Only the latest approved version stays active and traceable across the organization.
“QUMAS EDMS moves organizations from static file storage to an “intelligent Quality Content Control” paradigm
Use Cases and Industries
Life Sciences (Pharma & Biotechnology): Ever since QUMAS’s inception, pharmaceutical and biotech firms have been its primary users ([2]). These companies must tightly control every step of drug development and manufacturing (R&D, clinical, production) under cGxP laws. Common use cases include:
- SOP & Quality Document Management: Maintain global SOP libraries with controlled lifecycles and international compliance (FDA, EMA, etc). For example, each new revision triggers training assignments and audit tracking ([18]) ([17]).
- Regulatory Submissions: Manage dossiers (CTDs) and renewals. QUMAS’s integration with eCTD workflows speeds authoring and compilation of final submissions to health authorities ([14]).
- CAPA/Deviation/Audit: Document incident investigations and track corrective actions in an organized way (often integrating CAPA functionality via connected QUMAS EQMS modules).
- Training & Certification: Ensures that personnel complete required training (and acknowledge understanding) on the latest procedures before performing regulated work ([17]).
These capabilities directly address industry pain points. In fact, Vertex Pharmaceuticals (a biotech firm) is a documented QUMAS EDMS customer: a 2014 QUMAS User Conference featured Vertex’s case study. Vertex reported using QUMAS DocCompliance to extend efficient document control out to partners and CROs, replacing insecure FTP/email processes ([6]). This real-world example describes QUMAS use for collaboration with external partners and CROs.
A study by Dassault notes that life sciences companies rank quality/compliance among their top priorities ([7]). Dassault’s QUMAS EDMS datasheet states that the system has more than 300 global customer deployments ([4]); it does not provide a sector-by-sector deployment breakdown. Table 2 below summarizes QUMAS EDMS usage by industry:
Table 2: Adoption of QUMAS EDMS by Industry Sector and Use Cases
| Industry Sector | Key Use Cases | Notes / Example |
|---|---|---|
| Pharmaceuticals & Biotech | SOP/document control, regulatory submissions (eCTD), CAPA/audit, training, chemical batch records ([1]) ([5]) | Vertex Pharmaceuticals uses QUMAS DocCompliance for partner collaboration ([6]). Dassault reports more than 300 global customer deployments overall, without a sector-specific total ([4]). |
| Medical-device manufacturers | Controlled quality-system documentation subject to applicable QMSR and Part 11 requirements | FDA’s QMSR became effective on February 2, 2026 and amends 21 CFR Part 820 by incorporating ISO 13485:2016 by reference ([21]). Dassault describes QUMAS EDMS as supporting Part 11 controls, but this does not establish medical-device-maker adoption or suitability for a particular use; each organization must assess and validate its intended use under applicable requirements ([12]). |
| Other Regulated Industries | General quality and compliance (e.g. food, chemicals, aerospace), CAPA/audit, document control | QUMAS has applicability in any highly regulated field requiring robust document/paperwork control ([2]). (For example, chemical/oil companies have used EDMS solutions for GMP-like processes.) |
Sources: The information above is drawn from Dassault/QUMAS documentation ([1]) ([5]) ([6]) ([2]) and industry compliance requirements ([22]) ([7]).
Geographic and Customer Size: QUMAS EDMS is deployed worldwide. While detailed market share data is proprietary, Dassault’s press materials note 370,000 customers of all solutions across industries ([23]), indicating broad reach. Dassault reports more than 300 global customer deployments for QUMAS EDMS, but does not publish a detailed customer-size or geographic breakdown in the cited datasheet ([4]). Customers range from multinational pharmas to regional biotech firms – essentially any organization where quality and regulatory compliance are mission-critical.
Case Study: Vertex Pharmaceuticals
At the QUMAS Global Connect 2014 user conference, Vertex Pharmaceuticals (a US-based biotech) presented a case demonstrating QUMAS deployment. Vertex had been using QUMAS DocCompliance EDMS for ~8 years to manage controlled documents. Their challenge was extending secure collaboration with external partners (CROs, contract manufacturers). By using QUMAS EDMS as a central hub – rather than FTP or email – Vertex streamlined content sharing while maintaining audit control ([6]) ([24]). This real-world example shows QUMAS being used for controlled collaboration with external partners. No public ROI metrics are reported in the cited account.
Data Analysis and Market Perspective
No independent market report publicly lists all QUMAS EDMS clients, but industry research confirms QUMAS as a major EDMS/EQMS player. Analysts identify Dassault (BIOVIA) and QUMAS as key vendors in life-science quality software ([25]). The global QMS for life sciences market reached USD 2.81 billion in 2024 and is projected to grow to USD 6.54 billion by 2033 at a 9.7% CAGR, driven by intensifying regulatory requirements and digital transformation ([26]). North America leads at approximately $1.13 billion (2024), while Asia Pacific is the fastest-growing region at 12.3% CAGR. Industry surveys indicate broad EDMS adoption, with pharma companies implementing these systems primarily for compliance and productivity ([22]). Key drivers include eCTD regulatory submissions, data integrity requirements, and the shift toward cloud-based quality platforms.
Regulatory Trends: Electronic-record and submission requirements can make EDMS important for regulated operations. At FDA, eCTD requirements apply to specified CDER and CBER submission types, while electronic submission standards remain optional but encouraged for certain categories, such as noncommercial INDs and blood submissions ([27]). QUMAS supports automated submissions and “right-first-time” authoring, which has helped customers achieve the cited 60% increase in on-target submissions ([5]). In February 2026, the FDA issued final Computer Software Assurance (CSA) guidance for computers and automated data-processing systems used in medical-device production or a medical-device quality management system. The guidance describes a risk-based approach to establishing confidence in that software; it does not automatically validate an EDMS or apply to every QUMAS deployment. Organizations must determine their systems’ intended use and continue to meet applicable predicate-rule and Part 11 obligations for electronic records and signatures ([28]) ([12]). Industry commentators note that streamlined EDMS implementations can significantly shorten time-to-market for new drugs, addressing concerns about patent cliffs and competition ([22]) ([9]).
Cloud Transition: Dassault emphasizes cloud deployment for QUMAS EDMS. The official site calls it “cloud-based electronic document management” ([1]) ([15]). This aligns with the trend towards SaaS in regulated IT (for faster updates and remote seat flexibility). In Dassault’s narrative, the “3DEXPERIENCE platform” enables customers to work from anywhere—a critical advantage in pandemic-era remote work ([7]). Indeed, the ability for dispersed teams to securely access and review quality documents from the cloud is a key usage scenario driving QUMAS adoption.
“Vertex reported using QUMAS DocCompliance to extend efficient document control out to partners and CROs, replacing insecure FTP/email processes
Platform and Integration
QUMAS EDMS is not a standalone point solution; it is often used in tandem with Dassault’s broader software suite (BIOVIA applications) and other enterprise systems (ERP, LIMS, SharePoint). The product page notes compatibility with underlying platforms like SharePoint, Documentum, Oracle, and SQL Server ([29]), reflecting that QUMAS EDMS can sit on various IT infrastructures. Dassault also positions QUMAS EDMS as part of an integrated “Total Quality” or Quality Management System (QMS) offering, sometimes referred to as BIOVIA Total Quality ([30]) ([7]). In practice, organizations may employ QUMAS EDMS for document control while using other QMS tools (e.g. for training or CAPA) in a unified manner. The “MyQUMAS” interface provides single-access to both EDMS and Quality processes, underscoring the platform approach ([31]).
Implications and Future Directions
The widespread use of QUMAS EDMS in life sciences has several implications:
- Quality Culture: Customers developing “quality as a culture” benefit from having a single system of record. This can lead to fewer FDA 483 observations related to missing procedures, as firms ensure all procedures are written and followed (as emphasized by FDA inspections) ([7]).
- Digital Transformation: As companies move towards digital labs and Industry 4.0, EDMS will increasingly integrate with process data (e.g. linking batch records in ERP/LIMS with SOPs in EDMS). Dassault’s larger vision situates QUMAS EDMS within a digital lifecycle platform – potentially enabling connections between product-design workflows and quality processes, helping bridge R&D and manufacturing compliance.
- AI and Data: Dassault has begun integrating AI capabilities into the QUMAS ecosystem. QUMAS Quality Intelligence now leverages data science and machine learning to analyze data generated by EDMS and EQMS applications, enabling predictive quality insights ([32]). More broadly, BIOVIA's platform incorporates generative AI and large language models (LLMs) across its scientific solutions ([33]). In February 2026, Dassault Systèmes and NVIDIA announced a strategic partnership to build a cross-industry industrial AI platform combining Virtual Twin technologies with NVIDIA AI infrastructure ([34]). The announcement does not describe a QUMAS-specific AI roadmap.
- Regulatory Evolution: Regulatory agencies have been actively updating requirements. In 2025, the European Commission consulted on draft revisions to EU GMP Chapter 4 and Annex 11 and a draft new Annex 22 on artificial intelligence. The consultation closed on 7 October 2025; the Commission page describes draft documents and does not state a final-issuance date ([35]). Systems like QUMAS must adapt to these evolving mandates; Dassault has signaled that their platform supports evolving FDA/EMA requirements ([36]) ([7]), and QUMAS already supports current EU Annex 11 standards by design ([37]). Ongoing compliance needs will sustain EDMS usage.
Conclusion
In summary, QUMAS EDMS from Dassault Systèmes is marketed for life sciences organizations, including pharmaceutical and biotechnology companies, that need to control documents and processes under applicable regulatory requirements ([38]). Dassault reports more than 300 global customer deployments for QUMAS EDMS ([4]) and cites customer-reported quality metrics ([5]). The platform’s vendor-described Part 11-supporting functionality, collaborative workflows, and integrated training and approval features can support quality-document processes; each regulated organization must validate its intended use and controls. Case examples like Vertex Pharma’s use case ([6]) illustrate real-world application. Looking forward, as regulators demand even greater accountability and as digital transformation continues, EDMS solutions like QUMAS are set to remain essential. The integration with Dassault’s 3DEXPERIENCE ecosystem may further extend its reach, enabling customers to connect quality management with broader product and process development lifecycles.
References: All factual claims above are supported by Dassault Systèmes/BIOVIA product literature and industry sources ([1]) ([39]) ([5]) ([6]) ([2]) ([7]), complemented by independent analyses where noted ([22]).
Sources / 39
Need Expert Guidance on This Topic?
Let's discuss how IntuitionLabs can help you navigate the challenges covered in this article.
I'm Adrien Laurent, Founder & CEO of IntuitionLabs. With 25+ years of experience in enterprise software development, I specialize in creating custom AI solutions for the pharmaceutical and life science industries.
The information contained in this document is provided for educational and informational purposes only. We make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability, or availability of the information contained herein. Any reliance you place on such information is strictly at your own risk. In no event will IntuitionLabs.ai or its representatives be liable for any loss or damage including without limitation, indirect or consequential loss or damage, or any loss or damage whatsoever arising from the use of information presented in this document. This document may contain content generated with the assistance of artificial intelligence technologies. AI-generated content may contain errors, omissions, or inaccuracies. Readers are advised to independently verify any critical information before acting upon it. All product names, logos, brands, trademarks, and registered trademarks mentioned in this document are the property of their respective owners. All company, product, and service names used in this document are for identification purposes only. Use of these names, logos, trademarks, and brands does not imply endorsement by the respective trademark holders. IntuitionLabs.ai is an AI software development company specializing in helping life-science companies implement and leverage artificial intelligence solutions. Founded in 2023 by Adrien Laurent and based in San Jose, California. This document does not constitute professional or legal advice. For specific guidance related to your business needs, please consult with appropriate qualified professionals.
Related Articles
GxP Managed Services: A 2025 Analysis for Life Sciences
A detailed 2025 analysis of the GxP managed services market for pharma & life sciences. Learn about trends, regulatory drivers, and GxP compliance challenges.
GxP Collaboration Platforms: 21 CFR Part 11 Compliance
Review how Microsoft Teams, SharePoint, Box, Egnyte, Slack, and Veeva Vault handle FDA 21 CFR Part 11 compliance and GxP document control in life sciences.
GxP Environmental Monitoring Systems: Small Biotech Guide
Comprehensive guide to GxP environmental monitoring systems (EMS) for small biotech. Review FDA 21 CFR Part 11, EU GMP Annex 1, and vendor selection criteria.